The Unique Pharmacological Characteristics of Mifepristone (RU486): From Terminating Pregnancy to Preventing Cancer Metastasis

Medicinal Research Reviews

Volumn 34, Issue 5, 2014, Pages 979-1000

  Chen, Jianzhong ^a,b   Wang, Jichuang ^a   Shao, Jingwei ^a   Gao, Yu ^a   Xu, Jianguo ^a   Yu, Suhong ^a   Liu, Zhenhua ^c   Jia, Lee ^a  

^a FUZHOU UNIVERSITY   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c FUJIAN PROVINCIAL HOSPITAL   (China)

Author keywords

Cancer metastasis prevention; Enterohepatic circulation; Metapristone; Mifepristone; Terminating pregnancy

Indexed keywords

CYCLIN DEPENDENT KINASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIFEPRISTONE; PROTEIN BCL 2; ABORTIVE AGENT;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER INHIBITION; CELL ADHESION; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENDOMETRIUM CANCER; ENTEROHEPATIC CIRCULATION; GLIOMA; HUMAN; MENINGIOMA; METASTASIS; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; POSTMENOPAUSE; PREGNANCY TERMINATION; PROSTATE CANCER; STOMACH ADENOCARCINOMA; UTERUS CONTRACTION; FEMALE; LIVER; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATION; THERAPEUTIC ABORTION;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, THERAPEUTIC; FEMALE; HUMANS; LIVER; MIFEPRISTONE; NEOPLASM METASTASIS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 84905500518     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21311     Document Type: Article

References (88)

1. HO PC, Ngai SW. Mifepristone and misoprostol. Curr Obstet Gynecol 1999;9:29-33.
2. Schaff EA. Mifepristone: Ten years later. Contraception 2010;81:1-7.
3. Vastag B. Effect of mifepristone approval on research remains to be seen. J Natl Cancer Inst 2000;92:1970-1971.
4. Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: Toxicology and safety in animal and human studies. Contraception 2003;68:409-420.
5. Im A, Appleman LJ. Mifepristone: Pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert Opin Pharmacother 2010;11:481-488.
6. Lahteenmaki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L, Luukkainen T. Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 1987;27:859-863.
7. Wang JC, Chen JZ, Shao JW, Wang LY, Lu YS, Zhu YW, Ou MR, Yu SH, Chen HJ, Jia L. Synthesis, spectral characterization and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486). AAPS J 2014;DOI: 10.1208/s12248-013-9559-2.
8. Cekan S, Aedo AR, Segersteen E, Van Look P, Messinis I, Templeton A. Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose. Hum Reprod 1989;4:131-135.
9. Heikinheimo O. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. J Steroid Biochem 1989;32:21-25.
10. Shi YE, Ye ZH, He CH, Zhang GQ, Xu JQ, Van Look PF, Fotherby K. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 1993;48:133-149.
11. Teng YN, Dong RQ, Wang BJ, Liu HJ, Jiang ZM, Wei CM, Zhang R, Yuan GY, Liu XY, Guo RC. Determinations of mifepristone and its metabolites and their pharmacokinetics in healthy female Chinese subjects. Yao Xue Xue Bao 2011;46:1241-1245.
12. Tang C, Bi HC, Zhong GP, Chen X, Huang ZY, Huang M. Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: Application to a pharmacokinetic study. Biomed Chromatogr 2009;23:71-80.
13. Jang GR, Wrighton SA, Benet LZ. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol 1996;52:753-761.
14. Khan KK, He YQ, Correia MA, Halpert JR. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: Selective inactivation of P450 3A4. Drug Metab Dispos 2002;30:985-990.
15. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, Reid JM, Ames MM, Munn DH. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: Absence of toxicity due to saturating absorption. Food Chem Toxicol 2008;46:203-211.
16. Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet 1997;33:7-17.
17. Zhang F, Xue J, Shao J, Jia L. Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discov Today 2012;17:475-485.
18. Kawai S, Nieman LK, Brandon DD, Udelsman R, Loriaux DL, Chrousos GP. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. J Pharmacol Exp Ther 1987;241:401-406.
19. Heikinheimo O, Haukkamaa M, Lahteenmaki P. Distribution of RU 486 and its demethylated metabolites in humans. J Clin Endocrinol Metab 1989;68:270-275.
20. Spitz IM, Bardin CW. Clinical pharmacology of RU 486-An antiprogestin and antiglucocorticoid. Contraception 1993;48:403-444.
21. Heikinheimo O, Lahteenmaki PL, Koivunen E, Shoupe D, Croxatto H, Luukkainen T, Lahteenmaki P. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod 1987;2:379-385.
22. Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lahteenmaki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem 1987;26:279-284.
23. Sartor O, Figg WD. Mifepristone: Antineoplastic studies. Clin Obstet Gynecol 1996;39:498-505.
24. DeMarzo AM, Beck CA, Onate SA, Edwards DP. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein. Proc Natl Acad Sci USA 1991;88:72-76.
25. DeMarzo AM, Onate SA, Nordeen SK, Edwards DP. Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor. Biochemistry 1992;31:10491-10501.
26. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: Only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 1994;54:3868-3877.
27. Zhu XO, Yang Z, Guo CM, Ni XT, Li JN, Ge YC, Myatt L, Sun K. Paradoxical stimulation of cyclooxygenase-2 expression by glucocorticoids via a cyclic AMP response element in human amnion fibroblasts. Mol Endocrinol 2009;23:1839-1849.
28. Afhuppe W, Sommer A, Muller J, Schwede W, Fuhrmann U, Moller C. Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system. J Steroid Biochem Mol Biol 2009;113:105-115.
29. Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, Tsai MJ, O'Malley BW. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci USA 2002;99:7940-7944.
30. Kashima H, Horiuchi A, Uchikawa J, Miyamoto T, Suzuki A, Ashida T, Konishi I, Shiozawa T. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma. Anticancer Res 2009;29:1023-1029.
31. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-1357.
32. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004;18:70-85.
33. Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 2011;11:207-218.
34. Tian XS, Wu GJ, Zhou WH, Sun JZ, Du YH. Mechanism of mifepristone on proliferation and apoptosis of a breast cancer cell line. J Shandong Univ 2008;46:470-474.
35. Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 2013;19:6163-6172.
36. Fjelldal R, Moe BT, Orbo A, Sager G. MCF-7 cell apoptosis and cell cycle arrest: Non-genomic effects of progesterone and mifepristone (RU-486). Anticancer Res 2010;30:4835-4840.
37. Liang Y, Hou M, Kallab AM, Barrett JT, El EF, Schoenlein PV. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: A role for TGFbeta1. Int J Oncol 2003;23:369-380.
38. Wiehle RD, Christov K, Mehta R. Anti-progestins suppress the growth of established tumors induced by 7, 12-dimethylbenz(a)anthracene: Comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol Rep 2007;18:167-174.
39. Benakanakere I, Besch-Williford C, Schnell J, Brandt S, Ellersieck MR, Molinolo A, Hyder SM. Natural and synthetic progestins accelerate 7, 12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clin Cancer Res 2006;12:4062-4071.
40. Bakker GH, Setyono-Han B, Henkelman MS, de Jong FH, Lamberts SW, van der Schoot P, Klijn JG. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 1987;71:1021-1027.
41. El EM, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998;51:149-168.
42. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 1989;125:1593-1598.
43. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 2004;10:5215-5225.
44. Schoenlein PV, Hou M, Samaddar JS, Gaddy VT, Thangaraju M, Lewis J, Johnson M, Ganapathy V, Kallab A, Barrett JT. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol 2007;31:643-655.
45. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-1470.
46. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H. The antiprogestin RU486 in advanced breast cancer: Preliminary clinical trial. Bull Cancer 1987;74:455-461.
47. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989;49:2851-2856.
48. Koper JW, Foekens JA, Braakman R, Lamberts SW. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. Cancer Res 1990;50:2604-2607.
49. Olson JJ, Beck DW, Schlechte J, Loh PM. Hormonal manipulation of meningiomas in vitro. J Neurosurg 1986;65:99-107.
50. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 1994;80:527-534.
51. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-866.
52. Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod 1994;9(Suppl 1):202-207.
53. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): Clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727-733.
54. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril 2005;84:1719-1726.
55. Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, de Jong H. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 1992;55:486-490.
56. Pinski J, Halmos G, Shirahige Y, Wittliff JL, Schally AV. Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486. J Clin Endocrinol Metab 1993;77:1388-1392.
57. Brandhagen BN, Tieszen CR, Ulmer TM, Tracy MS, Goyeneche AA, Telleria CM. Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics. BMC Cancer 2013;13:35-49.
58. Ramaswamy R, Ashton K, Lea R, Roberts P, Davis CH, Golash A, Dawson T. Study of effectiveness of mifepristone for glioma cell line growth suppression. Br J Neurosurg 2012;26:336-339.
59. Llaguno-Munive M, Medina LA, Jurado R, Romero-Pina M, Garcia-Lopez P. Mifepristone improves chemo-radiation response in glioblastoma xenografts. Cancer Cell Int 2013;13:29-36.
60. Liang Y, Eid MA, El EF, Lewis RW, Kumar MV. Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. Int J Oncol 2002;21:1259-1267.
61. El EM, Liang Y, Lewis RW. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate 2000;43:31-42.
62. El EM, Liang Y, Johnson MH, Lewis RW. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 2000;42:99-106.
63. Gabaglia CR, DeLaney A, Gee J, Halder R, Graham FL, Gauldie J, Sercarz EE, Braciak TA. Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice. J Transl Med 2010;8:98-107.
64. Eid MA, Lewis RW, Kumar MV. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). Mol Cancer Ther 2002;1:831-840.
65. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 2008;101:1084-1089.
66. Goyeneche AA, Seidel EE, Telleria CM. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Invest New Drugs 2012;30:967-980.
67. Goyeneche AA, Caron RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007;13:3370-3379.
68. Freeburg EM, Goyeneche AA, Telleria CM. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol 2009;34:743-755.
69. Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer 2012;12:200-215.
70. Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM. Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Cancer Cell Int 2009;9:4.
71. Wempe SL, Gamarra-Luques CD, Telleria CM. Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells. Cancer Growth Metastasis 2013;6:1-13.
72. Rocereto TF, Saul HM, Aikins JJ, Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 2000;77:429-432.
73. Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J, Mannel RS. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study. Gynecol Oncol 2010;116:332-334.
74. Navo MA, Smith JA, Gaikwad A, Burke T, Brown J, Ramondetta LM. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol 2008;62:483-489.
75. Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G. Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res 2009;29:1047-1052.
76. Moe BT, Vereide AB, Orbo A, Sager G. High Concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. Anticancer Res 2009;29:1053-1058.
77. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K, Du YH. Effects of mifepristone on invasive and metastatic potential of human gastric adenocarcinoma cell line MKN-45 in vitro and in vivo. World J Gastroenterol 2004;10:1726-1729.
78. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K, Du YH. Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro. World J Gastroenterol 2004;10:2628-2631.
79. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K, Du YH. Reversal of multidrug resistance in drug-resistant human gastric cancer cell line SGC7901/VCR by antiprogestin drug mifepristone. World J Gastroenterol 2004;10:1722-1725.
80. Sun QL, Zhang XG, Xing QT, Ding P, Feng JB, Wu XP, Wang ZM. A study of mifepristone/IFN-gamma-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro. OncoTargets Ther 2012;5:335-342.
81. Jurado R, Lopez-Flores A, Alvarez A, Garcia-Lopez P. Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: An in vitro and in vivo study. Oncol Rep 2009;22:1237-1245.
82. Check JH, Dix E, Sansoucie L, Check D. Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon-case report. Anticancer Res 2009;29:1611-1613.
83. Esteve JL C, Acosta R, Pérez Y, Campos R, Hernández AV, Texidó CS. Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: Double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol 2012;161:202-208.
84. Tristan M, Orozco LJ, Steed A, Ramirez-Morera A, Stone P. Mifepristone for uterine fibroids. Cochrane Database Syst Rev 2012;8:D7687.
85. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009;21:318-324.
86. Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod 2008;23:2072-2079.
87. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227-233.
88. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 2009;115:1867-1874.